Your search for oral corticosteroids returned 4 results

Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.

Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).

AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.

Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company’s LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.